New therapeutic perspectives with low-affinity NMDA receptor antagonists;NEUE THERAPEUTISCHE MOGLICHKEITEN MIT NIEDERAFFINEN NMDA-REZEPTORANTAGONISTEN

Nervenarzt

Volumn 67, Issue 1, 1996, Pages 77-82

  Kornhuber, J ^a   Weller, M ^b  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Alzheimer type dementia; amantadine; glutamate; memantine; N methyl D aspartate; Parkinson's disease

Indexed keywords

AMANTADINE; BUDIPINE; DIZOCILPINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; AMINO ACID RECEPTOR BLOCKING AGENT; ANTIPARKINSON AGENT; GLUTAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYLASPARTIC ACID; PHENCYCLIDINE RECEPTOR;

HUMAN; MENTAL DISEASE; SHORT SURVEY; AGED; ALZHEIMER DISEASE; DRUG ANTAGONISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

AGED; ALZHEIMER DISEASE; AMANTADINE; ANTIPARKINSON AGENTS; EXCITATORY AMINO ACID ANTAGONISTS; GLUTAMINE; HUMANS; MEMANTINE; N-METHYLASPARTATE; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, PHENCYCLIDINE;

EID: 0029685858     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (22)

1. Bormann J (1989) Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacol 166: 591-592
2. Bouvier M, Szatkowski M, Amato A, Attwell D (1992) The glial cell glutamate uptake carrier countertransports pH-changing anions. Nature 360: 471-474
3. Chen HS, Pellegrini JW, Aggarwal SK, Lei SZ, Warach S, Jensen FE, Lipton SA (1992) Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci 12: 4427-4436
4. Clements JD, Lester RAJ, Tong G, Jahr CE, Westbrook GL (1992) The time course of glutamate in the synaptic cleft. Science 258: 1498-1501
5. Görtelmeyer R, Erbler H (1992) Memantine in the treatment of mild to moderate dementia syndrome. A double-blind placebo-controlled study. Arzneimittelforschung/Drug Res 42: 904-913
6. Klockgether T, Turski L (1989) Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease. Trends Neurosci 12: 285-286
7. Kornhuber J, Bormann J, Hübers M, Rusche K, Riederer P (1991) Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study. Eur J Pharmacol Mol Pharmacol Sect 206: 297-300
8. 3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 166: 589-590
9. Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W, Riederer P (1995) Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology 7: 713-721
10. Kornhuber J, Schoppmeyer K, Riederer P (1993) Affinity of 1-aminoadamantanes for the oσ binding site in post-mortem human frontal cortex. Neurosci Lett 163: 129-131
11. Kornhuber J, Weller M (1994) Aktueller Stand der biochemischen Hypothesen zur Pathogenese der Schizophrenien. Nervenarzt 65: 741-754
12. Kornhuber J, Weller M (1995) Predicting psychotomimetic properties of PCP-like NMDA receptor antagonists. In: Fog R, Gerlach J, Hemmingsen R. Krogsgaard-Larsen P, Thaysen JH (eds) Schizophrenia - an integrated view. Alfred Benzon Symposium 38. Munksgaard. Copenhagen, pp 314-325
13. Kornhuber J, Weller M, Schoppmeyer K, Riederer P (1994) Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. J Neural Transm [Suppl] 43: 91-104
14. Lipton SA, Rosenberg PA (1994) Excitatory amino acids as a final common pathway for neurological disorders. N Engl J Med 330: 613-622
15. Parsons CG, Gruner R, Rozcntal J, Millar J, Lodge D (1993) Patch clamp studies on the kinetic and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 32: 1337-1350
16. Parsons CG, Quack G, Bresink I, Baran L, Przegalinski E, Kostowski W, Krzascik P, Hartmann S, Danysz W (1995) Comparison of the potency, kinetics and voltage-dependency of open channel blockade for a series of uncompetitive NMDA antagonists in vitro with anticonvulsive and motor impairment activity in vivo. Neuropharmacology (in press)
17. Porter RHP, Greenamyre JT (1995) Regional variations in the pharmacology of NMDA receptor channel blockers: implications for therapeutic potential. J Neurochem 64: 614-623
18. Rao TS, Kim HS, Lehmann J, Martin LL, Wood PL (1990) Interactions of phencyclidine receptor agonist MK-801 with dopaminergic system: regional studies in the rat. J Neurochem 54: 1157-1162
19. Szatkowski M, Attwell D (1994) Triggering and execution of neuronal death in brain ischaemia: two phases of glutamate release by different mechanisms. Trends Neurosci 17: 359-365
20. Teitelbaum JS, Zatorre RJ, Carpenter S, Gendron D, Evans AC, Gjedde A, Cashman NR (1990) Neurologic sequelae of domoic acid intoxication due to the ingestion of contaminated mussels. N Engl J Med 322: 1781-1787
21. Weller M, Finiels-Marlier F, Paul SM (1993) NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine. Brain Res 613: 143-148
22. Weller M, Kornhuber J (1992) Pathophysiologie und Therapie des malignen neuroleptischen Syndroms. Nervenarzt 63: 645-655